PL Bernard

Post doc Eyquem Lab UCSF | PhD in Immunology | Cytotoxic lymphocytes

[PL Bernard @PL_Bernard]

Almost a year later and these charts still have me squinting! Quite the adventure, fueled by an amazing amount of energy and talent from our team alongside collaborators. @UCSF @GladstoneInst

[Justin Eyquem @j_eyquem]

We have been asked many times: could in vivo generated CAR T cells work in solid tumors? @PL_Bernard tested it and

YES!

In a uterine Sarcoma model, we show that a single injection of vectors delivering a TRAC-B7H3-CAR can achieve complete responses in our humanized mouse model

[PL Bernard @PL_Bernard]

@AnaisRger

[PL Bernard @PL_Bernard]

@AnaisRger @crcm_marseille @GeoffGuittard @NUNESJacques1 @laliguecancer @TumImmuno_CRCM

[PL Bernard @PL_Bernard]

After 4 years of thesis work at @crcm_marseille, I'm now a doctor !

A huge thank you to @GeoffGuittard and @NUNESJacques1 for trusting me and teaching me so much.
Thanks to @laliguecancer for the support.

Time to leave the nest now, and what a nest it was!
@TumImmuno_CRCM

[PL Bernard @PL_Bernard]

@laliguecancer @crcm_marseille Merci à @laliguecancer de soutenir le projet depuis le début !
L'enjeu maintenant est de concrétiser ces résultats, dans l'intérêt des patientes et des patients 🙏
@GeoffGuittard @NUNESJacques1

[PL Bernard @PL_Bernard]

Twice in a row.

[Eddy Pasquier @eddpasquier]

I’ll probably never get an #ERC grant, but last night, thanks to a fantastic team, I did win something BIG: the legendary blindtest of @crcm_marseille.

Apologies to @TumImmuno_CRCM and @ChrisGinestier. You guys will do better next time 🤪

[Cancer Research @CR_AACR]

From the September 15 issue—
CD25high Effector Regulatory #TCells Hamper Responses to PD-1 Blockade in Triple-Negative #BreastCancer, by Fattori et al.
https://t.co/8IaBgY7LUX
@anne_chretien @TumImmuno_CRCM

[Geoffrey Guittard @GeoffGuittard]

Hello everyone,

We are recruiting a 3-yearpost-doc in immunity and Cancer team in Marseille (France) to work on cell therapy in immuno-oncology. Please contact me if you are interested [email protected] or transfer this offer to find the ideal candidate.

Thanks !

[Geoffrey Guittard @GeoffGuittard]

Such a plesure to close this tremendous scientific meeting thank you again to the canceropole for this great opportunity.

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors https://t.co/BDEyGT6Po4 @MyeLau_Gorvel @NUNESJacques1 @GeoffGuittard

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC review: Negative intracellular regulators of T-cell receptor (TCR) signaling as potential antitumor immunotherapy targets https://t.co/bwmfUokSFI @lavolodon @PL_Bernard @GeoffGuittard @NUNESJacques1

[PL Bernard @PL_Bernard]

@AnaisRger

[Immunity & Cancer Team - Marseille @TumImmuno_CRCM]

Brand new published protocol from @TumImmuno_CRCM !

You'll discover here some secrets of the platform, on how we can generate high dimension data and explore the immune system of cancer patients.

https://t.co/SZSB4kVxEt

[Eddy Pasquier @eddpasquier]

Here it is !!!

The very first paper of the #REMAP4Kids team was published today in @eBioMedicine (although we won’t be officially created before Jan 2024).

https://t.co/k0g5LRgu4v

A quick thread to explain what we found.

1/n

[France Culture @franceculture]

Une étude parue dans la revue "Cell" décrit l’identification d’un mécanisme épigénétique propre aux femmes, qui est impliqué dans le développement de tumeurs agressives.
https://t.co/PzlBN60sCT

[PL Bernard @PL_Bernard]

And of course, warm thanks to @laliguecancer for supporting my PhD project since 2019.

[PL Bernard @PL_Bernard]

Thrilled to share my first research paper out in @jitcancer ! Huge thanks to every person involved @EricVivier1 @Dr_Nick_Bikes, and especially to @NUNESJacques1 & @GeoffGuittard

Stay tuned for more exciting data from @TumImmuno_CRCM !

[Journal for ImmunoTherapy of Cancer @jitcancer]

New #JITC article: Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity https://t.co/lOVIgbGy0G @PL_Bernard @NUNESJacques1 @GeoffGuittard